International Clinical Trial: An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07461727) titled 'An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases' on March 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Condition: Non-Small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Liver Metastases EGFR Gene Mutat...